While an increasing number of options exist for effectively treating patients with HIV infection, many clinicians find it challenging to keep abreast of important developments in HIV therapeutics. To address this problem, this CME dinner program series will use case studies to highlight and discuss the relative merits and clinical significance of new findings in HIV medicine presented at the 22nd Conference on Retroviruses and Opportunistic Infections (CROI 2015). Because the focus of the dinner programs will be on case studies, participants will need to be familiar with data from CROI 2015 that may be applied and discussed. Therefore, prior to attending a dinner program, participants will view an Internet presentation that summarizes and discusses the key data presented at CROI 2015. As a result of this program, participants will not only gain an increased understanding of key data presented at CROI 2015, they will also be prepared to use these data in the clinic to address HIV-positive patients' health needs and provide the optimal care available, which will help to improve virologic suppression and antiretroviral drug adherence, increase the delivery of individualized care, reduce resistance and treatment failure, and improve patient outcomes and quality of life.
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at CROI 2015 and it is not sanctioned by CROI 2015.
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.
After completing this activity, the participant should be better able to:
Use in a clinical setting findings from key new studies on HIV/AIDS diagnosis, management and treatment presented at CROI 2015
Employ the current treatment paradigms for HIV/AIDS, including the studies and data presented at CROI 2015
to improve patient care
Discuss with patients and colleagues the studies and data
on newer therapies for HIV/AIDS presented at CROI 2015 and use that discussion to decide on appropriate planning
of therapy for patients with HIV/AIDS
| Tuesday, March 3, 2015 New York, NY |
Tuesday, March 10, 2015 San Diego, CA |
| Wednesday, March 4, 2015 San Francisco, CA |
Wednesday, March 11, 2015 Chicago, IL |
|
Thursday, March 5, 2015 Los Angeles, CA |
Tuesday, March 17, 2015 Miami, FL |
| Tuesday, March 10, 2015 Phoenix, AZ |
Thursday, March 26, 2015 Houston, TX |
| Ian Frank, MD Professor of Medicine Director, Clinical Therapeutics Program Penn Center for AIDS Research Perelman School of Medicine at the University of Pennsylvania Philadelphia, Pennsylvania |
Trevor Hawkins, MD Chief Medical Officer Southwest C.A.R.E. Santa Fe, New Mexico |
|
Eric S. Daar, MD Chief, Division of HIV Medicine Vice Chair Department of Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Los Angeles, California |
Charles B. Hicks, MD Professor of Clinical Medicine Director, Owen Clinic University of California, San Diego San Diego, California |
|
W. David Hardy, MD Professor of Medicine David Geffen School of Medicine at UCLA Los Angeles, California |
|
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
As of August 1, 2013, pharmaceutical companies are required by the open payments act (AKA Sunshine Act) to account for certain transfers of value provided to physicians. The federal guidance for the Sunshine Act provides exceptions for CME expenses that meet certain criteria. We believe the program to which you are invited meets these exceptions, and therefore we will not be collecting, nor reporting, any information gathered from this program. If federal guidance is further clarified in the future, we will then provide that information to the supporting pharmaceutical companies to the best of our ability.
The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
Supported by an independent educational grant from Gilead Sciences Medical Affairs.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.
